obesity

News

Noom offers cut-price compounded GLP-1 drug for obesity

Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US.

News

Study backs role of Novo Nordisk obesity drug in children

A clinical trial has backed the safety and efficacy of one of Novo Nordisk's weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI).

News

Terns files $125m financing after positive obesity data

Fresh from reporting encouraging results with its oral weight-loss drug, Terns Pharma has moved swiftly ahead with a public offering, seeking to raise upwards of $125 million to fund additi

News

Samir Ounzain, CEO and co-founder of Haya Therapeutics

Lilly to hunt non-coding DNA for obesity drugs in $1bn deal

Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.

News

Lilly launches single-dose Zepbound to ease self-pay access

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford

News

Study reignites debate on GLP-1 drugs and suicide risk

A study has found a higher risk of suicidal thoughts in users of Novo Nordisk's GLP-1 agonist-based drugs for diabetes and obesity, even though regulators in the US and EU concluded there w

Noom offers cut-price compounded GLP-1 drug for obesity

Study backs role of Novo Nordisk obesity drug in children

Terns files $125m financing after positive obesity data

Lilly to hunt non-coding DNA for obesity drugs in $1bn deal

Lilly launches single-dose Zepbound to ease self-pay access

Study reignites debate on GLP-1 drugs and suicide risk

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

obesity

Editor's Picks